A Novel Homozygous Missense Mutation in the Apo A-I Gene With Apo A-I Deficiency

From the Departments of Internal Medicine (W.H., J.S., A.M., H.H., M.K., T.K., K.A.) and Biochemistry (K.M.), Fukuoka University School of Medicine, Fukuoka; and the Department of Internal Medicine, Oita Prefectural Hospital, Oita (H.N., K.Y.), Japan.

Correspondence to Jun Sasaki, MD, Department of Internal Medicine, School of Medicine, Fukuoka University, 45–1, 7-chome Nanakuma, Jonan-ku, Fukuoka 814–80, Japan. E-mail mm034505{at}msat.fukuoka-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—We analyzed the genetic defect in a 67-year-old Japanese male patient with apolipoprotein (apo) A-I and high density lipoprotein (HDL) deficiencies, corneal opacities, and coronary artery disease. The plasma concentrations of apoA-I and HDL cholesterol were 2.9 to 7.3 mg/dL and 0.08 to 0.19 mmol/L, respectively. The lecithin:cholesterol acyltransferase (LCAT) activity and cholesterol esterification rate were <40% of normal control values. LCAT mass was 50% of normal control. Sequence analysis of polymerase chain reaction–amplified DNA of the proband's apoA-I gene showed a homozygous T-to-A transition resulting in the substitution of Val 156 with Glu (apoA-I Oita). Direct sequencing of samples obtained from other family members showed that the brother was homozygous, whereas the son was a heterozygous carrier of apoA-I Oita. The heterozygote for apo A-I Oita showed nearly 60% of normal apoA-I and normal HDL cholesterol levels. In vivo turnover studies in rabbits demonstrated that the variant apoA-I was rapidly cleared from plasma compared with normal human apoA-I. Our data suggest that the Val156Glu substitution is associated with apoA-I and HDL deficiency, partial LCAT deficiency, and corneal opacities and that Val156 of apoA-I may play an important role in apoA-I function.

Key Words: HDL deficiency • apolipoprotein variant • apoA-I Japanese • corneal opacities

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Apolipoprotein A-I is composed of 243 amino acid residues that fold into amphipathic helixes, thus forming functional domains. ApoA-I plays a leading role in HDL-mediated cholesterol efflux from peripheral cells and acts as a cofactor for LCAT activation.¹ The functional domains of apoA-I have been recently examined by using monoclonal anti–apoA-I antibodies, mutagenized apoA-I, and immunochemical and physicochemical approaches.^{1 2} In addition, naturally occurring mutations in the apoA-I gene have been structurally and functionally characterized to be the underlying molecular defects of low HDL levels.^{3 4 5} These data suggest that the functional domains of apoA-I contain central amphipathic -helixes involving amino acid residues between 137 and 186, which are critical for both activation of LCAT and enhancing cholesterol efflux from peripheral cells.

More than 10 apoA-I gene defects of either a deletion or insertion leading to HDL deficiency have been reported.^{5 6 7 8 9 10 11 12 13 14 15} However, in subjects with HDL deficiency, CAD is not always present. In addition, 40 heterozygous structural apoA-I variants with a single amino acid substitution have been characterized.^{2 16 17 18 19 20 21} However, most of these variants do not affect HDL concentration except for nine that are associated with reduced plasma apoA-I and HDL cholesterol levels.^{17 18 19 20 21 22 23 24 25} In this article we report a novel, homozygous, missense point mutation in the apoA-I gene that is associated with apoA-I and HDL deficiencies, corneal opacities, and CAD.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
A 67-year-old Japanese man was admitted to Oita Prefectural Hospital because of worsening effort-dependent chest oppression, which was first experienced 3 months before admission. His body mass index was 27.5 kg/m². He had smoked 50 cigarettes per day for 50 years. Physical examination showed bilateral corneal opacities, and the blood pressure was 130/70 mm Hg. There was no tonsillar hypertrophy, tendinous xanthomata, hepatosplenomegaly, or peripheral neuropathy. Serum concentrations of apoA-I and HDL cholesterol were markedly low (2.9 to 7.3 mg/dL and 0.08 to 0.19 mmol/L, respectively). Other laboratory findings were within the normal range. A coronary arteriogram showed 90% stenosis of the left main trunk and 75% stenosis of the proximal portion of the left anterior descending artery and circumflex artery. Aortocoronary bypass surgery was performed. Complete occlusion of the left internal carotid artery, stenosis of the right proximal internal carotid artery, complete occlusion of the left vertebral artery, and stenosis of the right vertebral artery were also detected on angiography. The pedigree for the proband is shown in Fig 1. Examination of other family members showed that the brother (II 1) also had bilateral corneal opacities, but neither the proband's son (III 1) nor his grandchildren (IV 1,2) had corneal opacities. The proband's elder brother (II 1) had no history of diabetes mellitus or hypertension or any symptom suggestive of CAD, and he also had a normal resting electrocardiogram. The proband's son (III 1) did not suffer from clinical symptoms or signs of CAD, and he had a normal resting and stress electrocardiogram. The proband's parents had died at 83 and 82 years of age. This study was approved by the Ethics Review Committee of the School of Medicine, Fukuoka University. The proband and his family members gave their informed consent prior to their participation in this study.

View larger version (16K): [in this window] [in a new window]   Figure 1. Pedigree of the apoA-I Oita family. Arrow indicates the proband.

Lipid, Apolipoprotein, and Lipoprotein Analyses
Blood samples were collected in tubes containing disodium EDTA after a 12-hour fast. Plasma concentrations of cholesterol and TG were determined by an enzymatic method. Apolipoprotein concentrations were measured by single radial immunodiffusion, and plasma lipoproteins were separated by sequential ultracentrifugation.⁵ The following density fractions were obtained: VLDL (d<1.006 g/mL), LDL (d=1.019 to 1.063 g/mL), HDL₂ (d=1.063 to 1.125 g/mL), and HDL₃ (d=1.125 to 1.21 g/mL). Fractionation of plasma lipoproteins by Superose 6HR 10/30 gel chromatography was performed with a fast protein liquid chromatography system (Pharmacia Fine Chemicals). The column matrix was equilibrated with PBS containing 1 mmol/L EDTA and 0.02% NaN₃ (pH 7.4). Fifty 0.5-mL fractions were collected at a flow rate of 0.5 mL/min. Electrophoresis of lipoproteins from the different plasma density fractions was performed by 12.5% SDS-PAGE, and the distribution of apoA-I was visualized with an ECL Western blotting kit (Amersham Life Science). Control samples for comparing plasma concentrations of lipids, lipoproteins, LCAT activity, and LCAT mass were obtained from healthy volunteers matched for age and sex. Informed consent was obtained from all control subjects.

Electrophoresis and Immunoblotting
IEF gel electrophoresis on a pH gradient from 4 to 6 using plasma samples from the proband and his family was performed as described previously.²⁶ In brief, 1 µL plasma was incubated at room temperature for 1 hour with 30 µL of 10 mmol/L Tris HCl (pH 8.2) containing 1% sodium decyl sulfate, 2% ampholytes (pH 4 to 6), and 10% ß-mercaptoethanol. The mini-slab gel system (Biometra-Multigel G-44, Biometra) with a 7.2% polyacrylamide gel containing 5 mol/L urea and 2% ampholytes (pH 4 to 6) was used for IEF. A two-dimensional gel electrophoresis of plasma, consisting of IEF followed by SDS-PAGE, was performed as described previously.¹¹ The apoA-I bands were identified by immunoblots with a polyclonal rabbit anti-human apoA-I antiserum.

Isolation of ApoA-I
HDLs (d=1.063 to 1.21 g/mL) were isolated from a 50- mL plasma sample from the proband and from a normal, healthy subject by preparative ultracentrifugation, delipidated, and then solubilized in deionized water.²⁶ Delipidated HDL was passed through a gel chromatography column on Sephacryl S-200. Variant apoA-I and normal apoA-I were isolated by Immobiline IEF, with a pH gradient ranging from 5 to 6 as described previously.²⁶

Iodination of ApoA-I
Labeling of normal human apoA-I and apoA-I Oita with Na[¹²⁵I] (Du Pont–New England Nuclear) was carried out according to the iodine monochloride method of McFarlane.²⁷ The labeled apoA-I was dialyzed at 4°C for 40 hours against 0.15 mol/L NaCl containing 0.3 mmol/L EDTA, pH 7.4. The specific activity of labeled apoA-I ranged from 350 to 450 counts per minute per nanogram protein, and 99% of the radioactivity in labeled apoA-I could be precipitated by trichloroacetic acid. Before the turnover studies, labeled apoA-I was passed through a 0.45- µm filter with the addition of bovine albumin (fatty acid free, Sigma Chemical Co) to a final concentration of 10 mg/mL and stored for 1 to 2 days at 4°C.

In Vivo Turnover Study of ApoA-I
Male Japanese White rabbits (body weight, 2.5 to 3.0 kg) were purchased from Kyudo Co, Fukuoka, Japan. The animals were housed individually in a 12-hour/12-hour light/dark cycle environment and provided with a commercial diet and water ad libitum. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of our institution. The procedures of in vivo turnover studies were performed essentially as described previously.²⁸ In brief, 2 days before and throughout the entire turnover study, five drops of saturated KI were added each day to the drinking water. Twenty-five µCi of ¹²⁵I-labeled apoA-I in 1 mL saline with 10 mg/mL bovine albumin was injected into each animal via the marginal ear vein. Blood samples were collected via the marginal ear vein at 5 minutes and at 3, 6, 9, and 24 hours after injection and then once a day for 6 days. The FCR was calculated as described by Matthews.²⁹ The clearance of each labeled apoA-I was measured in four different rabbits.

Haplotype Analysis
We determined the apoE genotype by using HhaI digestion of the apoE gene after amplification by PCR as reported by our laboratory.³⁰ ApoA-I MspI and apoC-III SstI polymorphisms were performed as previously reported.³¹

Nondenaturing Gradient PAGE
HDL particle sizes were determined by nondenaturing gradient PAGE on 4% to 30% gels (Pharmacia LKB Biotechnology).³² Plasma with a d<1.21g/mL was obtained by ultracentrifugation at 100 000 rpm for 2 hours (Beckman TL-100 ultracentrifuge). This was followed by the addition of 20 µg protein to the gel. Protein was visualized with 0.05% Coomassie brilliant blue G-250, and then the gel was scanned with a personal densitometer SI (Molecular Dynamics Inc). The gel was calibrated with a standard protein mixture (high-molecular-weight calibration kit, Pharmacia LKB Biotechnology). HDL particles size was calculated from the calibration curve of the peak migration distance versus that of the standard.

CER, LCAT Activity, and LCAT Mass Measurements
CER indicates the esterification of endogenous cholesterol, which was determined by the method of Stokke and Norum.³³ LCAT activity was measured by using a proteoliposome as a substrate.³⁴ LCAT mass was kindly assayed by Prof John J. Albers, University of Washington, Department of Medicine, Northwest Lipid Research Laboratories, Seattle, Wash.³⁵

DNA Amplification by PCR
Genomic DNA was isolated from 120 µL peripheral blood as described in the Genomix kit manual (Talent srI). Ten microliters of this extract was used as a template for PCR. Oligonucleotide primers for the apoA-I gene were synthesized on the basis of published data (model 380B DNA synthesizer, Applied Biosystems). The primers for the apoA-I gene are listed in Table 1. PCR was performed according to the protocol published by the manufacturer with the use of a Perkin Elmer–Cetus thermal cycler. Amplification was performed by initial denaturation at 96°C for 10 minutes, followed by 30 cycles at 96°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute, and a final extension for 7 minutes at 72°C. A reaction volume of 100 µL contained 2.5 U Taq polymerase (Perkin Elmer–Cetus), 150 ng genomic DNA, 20 pmol of each primer, and 200 µmol of each dNTP in 10x reaction buffer containing 0.1 mol/L Tris HCl, pH 8.3, 0.5 mol/L KCl, 15 mmol/L MgCl₂, and 0.1% (wt/vol) gelatin, as described previously.²⁶

DNA Sequence Analysis
The PCR-amplified DNA products were purified with a GeneClean kit (Bio101), and purified DNA fragments were ligated to the pT7Blue-T vector (Novagen). Twelve clones of both strands in opposite directions were sequenced by the dideoxy chain- termination method using Sequenase (US Biochemical).³⁷ The DNA fragment around the mutation in exon 4 of apoA-I was amplified and subjected to direct sequencing by using a DNA sequencing kit (dye terminator cycle sequencing ready reaction, Perkin Elmer) with an ABI 373 DNA sequencer.

Statistical Analysis
Data are expressed as mean±SD. Differences in FCR in the turnover study were evaluated for statistical significance by Student's t test. A value of P <.05 denoted statistical significance.

	Results

Top Abstract Introduction Methods Results Discussion References

 
DNA Sequence Analysis
Three pairs of oligonucleotide primers were used to amplify exons and exon-intron boundaries of the apoA-I gene by PCR. Nucleotide numbers were based on the published sequence for apoA-I DNA.³⁶ Fig 2A shows an autoradiogram of the sequencing results around region 1762 in exon 4 of the apoA-I gene. A T-to-A substitution was detected at position 1762 of exon 4 in all 12 clones of the subcloned DNA fragment from the proband, resulting in a single amino acid change (Glu for Val) at residue 156. Since this substitution has not been previously reported, we termed this apoA-I variant (Val156Glu) "apoA-I Oita" owing to the residence of the proband. Other parts of the apoA-I gene were identical to the wild type, except for a -75 G- to- A variation in the promoter region. Further direct sequence analysis showed that the brother of the proband was also homozygous for apoA-I Oita, whereas the proband's son was heterozygous (Fig 2B); however, the two grandchildren did not carry this mutant allele.

View larger version (35K): [in this window] [in a new window]   Figure 2. DNA sequence analysis for apoA-I gene. A, Autoradiogram of a portion of apoA-I gene exon 4 from a normal subject (left) and the proband with apoA-I Oita (right). A T-to-A substitution at nucleotide 1762 was detected, creating a Val- to- Glu substitution at codon 156. The asterisk indicates the position of the T-to-A substitution. B, Direct sequence analysis of the same portion of the apoA-I gene exon 4 for the apoA-I Oita family. PCR-amplified DNA around the mutation was purified with a GeneClean kit and then subjected to direct sequencing with an ABI 373 DNA sequencer. This process yields information on both alleles. B-1, A wild- type sequence pattern of apoA-I exon 4 around nucleotide 1762; B-2, a heterozygous T-to-A substitution (arrow) at nucleotide 1762; and B-3, a homozygous T-to-A substitution at nucleotide 1762. Nucleotide numbers are based on the published sequence for apoA-I DNA.36

Lipid, Apolipoprotein, and Lipoprotein Profiles
The concentrations of lipids, lipoproteins, and apolipoproteins in members of the family with apoA-I Oita are shown in Tables 2 and 3. The concentrations of total cholesterol, TG, and LDL cholesterol in the proband were within normal levels. The free cholesterol–to–total cholesterol ratio in the proband was slightly higher in the total, VLDL, and LDL fractions but threefold higher in the HDL fraction than those of nonaffected family members, indicating that esterification of cholesterol was reduced mainly in the HDL fraction (Table 4). The proband and his brother had <10% and <15%, respectively, of normal apoA-I and HDL cholesterol levels. The proband's son had nearly 60% of normal apoA-I and HDL cholesterol levels, whereas these two parameters were normal in other family members. Although cholesterol concentrations in both HDL₂ and HDL₃ subfractions were markedly reduced, the degree of reduction in the HDL₂ subfraction was higher than that in HDL₃ in either homozygotes or heterozygotes. Plasma lipoproteins separated by gel chromatography from the proband showed a rearrangement of TGs among plasma lipoproteins (Fig 3). The TG of the proband was distributed mainly in the LDL fraction instead of in VLDL, a characteristic similar to that of normal control subjects. The cholesterol level in the HDL fraction was markedly reduced, whereas TG was only slightly decreased. The distribution of apoA-I was shifted to a higher density fraction of HDL (Fig 3). ApoC-II and apoC-III were at moderately low levels in the homozygote, whereas apoB and apoE concentrations were within the normal range. ApoE genotype was E3/E3 in all family members tested in the present study.

View larger version (29K): [in this window] [in a new window]   Figure 3. Gel filtration chromatography of plasma lipoproteins. A, Samples from a normal subject; B, sample from the proband of apoA-I Oita. TG () and cholesterol () contents of each fraction were measured enzymatically. In the inset each lipoprotein fraction was subjected to 12.5% SDS-PAGE followed by Western blotting.

Plasma CER, LCAT Activity, and LCAT Mass
Analysis of CER, LCAT activity, and LCAT mass showed that these parameters were 50% lower in homozygous apoA-I Oita carriers than in normal control subjects but were not different from those in heterozygous carriers (Table 5). These data indicate that the partial reductions in LCAT activity and mass in this case may be secondary to a Val156Glu substitution in apoA-I rather than a defect in the LCAT gene itself.

Electrophoresis and Immunoblots
IEF of plasma at a pH range of 4 to 6 followed by immunoblotting showed no apoA-I-4 band in the proband (II 2) or his brother (II 1) but rather showed apoA-I-3 and apoA-I-5 bands. In contrast, a plasma sample from the proband's son (III 1) showed apoA-I-2, apoA-I-4, and faint apoA-I-3 and apoA-I-5 bands (Fig 4). Two-dimensional electrophoresis (IEF and SDS) followed by immunoblotting showed that the molecular weights of apoA-I-3 and apoA-I-5 bands of the proband were similar to that of normal apoA-I (data not shown). The nondenaturing gradient gel electrophoresis of HDL particles followed by scanning with a personal densitometer SI is shown in Fig 5. In the homozygous proband (II 2), the HDL fraction was hardly observed. In the heterozygote (III 1), HDL particle size was smaller than that in normal control subjects.

View larger version (39K): [in this window] [in a new window]   Figure 4. IEF gel electrophoresis of plasma followed by immunoblotting was performed at pH 4 to 6. Lane N, normal control; lane 1, the proband (II 2); lane 2, his brother (II 1); lane 3, the proband's son (III 1); and lanes 4 and 5, the proband's two grandsons (IV 1, IV 2).

View larger version (15K): [in this window] [in a new window]   Figure 5. HDL particle size profiles. Densitometric scanning was performed after nondenaturing gradient (4% to 30%) PAGE of HDL particles isolated from the proband homozygous for apoA-I Oita (top, II 2), a heterozygous family member (center, III 1), and a normal subject (bottom). The HDL subpopulation intervals are indicated below the scan profiles.

Haplotype Analysis
The results of apoC-III SstI, apoA-I MspI, and apoA-I promoter (-75G/A) polymorphisms are shown in Table 3. Haplotypes S1S1, M1M1, and AA were observed in both the proband (II 2) and his brother (II 1). The distribution pattern of these three markers in the apoA-I Oita family was compatible with that of an apoA-I Oita mutant allele in the pedigree.

In Vivo ApoA-I Kinetic Study
Plasma decay curves of ¹²⁵I-labeled normal and variant apoA-I in rabbits are shown in Fig 6. The turnover of¹²⁵I-labeled apoA-I Oita was markedly faster than that of ¹²⁵I-labeled normal human apoA-I. The mean FCR of ¹²⁵I-labeled apoA-I Oita was more than double that of ¹²⁵I-labeled normal human apoA-I (Table 6).

View larger version (16K): [in this window] [in a new window]   Figure 6. Clearance of 125I-labeled human normal apoA-I and apoA-I Oita from plasma of normal rabbits. Data represent percentages of the injected dose of either normal 125I-apoA-I () or 125I-apoA-I Oita () remaining in the plasma of rabbits throughout the experiment.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The major finding of the present study was the identification of a novel, homozygous, missense point mutation, apoA-I (Val156Glu) Oita, in exon 4 of the apoA-I gene that was found to be associated with markedly low levels of apoA-I and HDL cholesterol, partial LCAT deficiency, corneal opacities, and CAD. The plasma concentrations of apoA-I and HDL cholesterol in the homozygous apoA-I Oita subjects were <15% of those in normal control subjects but were 60% of the control values in the heterozygote. We also observed a gene- dosage effect of the apoA-I Oita mutant allele on apoA-I and HDL cholesterol levels in this family.

More than 10 cases of homozygous apoA-I defects caused by a nonsense mutation, a deletion, and an insertion have been reported to be associated with apoA-I and HDL deficiency. The clinical manifestation in these cases was variable and included premature atherosclerosis, xanthomatosis, and corneal opacities. Premature CAD was clearly reported in only four cases.^{6 7 8 13} In contrast, 40 structural apoA-I variants have been reported, although most of them are not associated with changes in HDL level or premature CAD except for nine cases.^{17 18 19 20 21 22 23 24 25} The reason for this phenomenon remains unclear, but it may be partly related to the fact that almost all patients with apoA-I variants characterized so far have been heterozygotes. Thus, these apoA-I variants have little dominant effect on lipoproteins metabolism in vivo. To our knowledge, a homozygous, missense point mutation in the apoA-I gene that is associated with clinical manifestations has not yet been reported. ApoA-I (Glu136Lys) was the first reported case of homozygosity for a structural apoA-I variant.³⁸ However, this apoA-I variant was not correlated with either HDL level or any clinical complication. Therefore, apoA-I (Val156Glu) Oita is the first well- documented report correlating homozygosity for an apoA-I variant with reduced HDL concentrations.

The mechanisms by which the apoA-I (Val156Glu) substitution in homozygosity influences HDL metabolism and results in clinical complications are probably complex. In vitro experiments with monoclonal antibodies and mutagenized apo A-I suggest that residues 143 to 164 of apoA-I are involved in the LCAT activation process.^{1 39} A naturally occurring mutation, apoA-I Seattle, with a deletion from Glu146 to Arg160, in heterozygosity was reported to be associated with a reduction in apoA-I and HDL cholesterol levels to below 15% of control values.¹¹ Four of six reported heterozygosities for apoA-I variants in this domain with a dominant effect on HDL metabolism are associated with reduced LCAT cofactor activity or LCAT activity per se. ApoA-I (Pro143Arg) Giessen has been isolated from plasma, and LCAT cofactor activity of the variant has been demonstrated to be 60% to 70% of that in control apoA-I.²² In another study, isolated apoA-I (Pro165Arg) from the proband's plasma was reconstituted into artificial discoidal HDL. The apoA-I (Pro165Arg) variant exhibited 30% to 70% of LCAT cofactor activity compared with that of normal apoA-I.⁴⁰ Low LCAT activity was also reported in apoA-I (Arg151Cys) Paris and apoA-I (Arg160Leu) Oslo.^{20 21} These data indicate the important role of residues 143 to 164 in apoA-I function, particularly the LCAT activation process. The reduced CER, LCAT activity, and LCAT mass but normal LCAT specific activity observed in the apoA-I Oita homozygote indicates a partial LCAT deficiency. The reduced LCAT activity in the apoA-I Oita homozygote is consistent with the elevated free cholesterol–to–total cholesterol ratio observed in the HDL fraction. Because the substitution of Val for Glu at residue 156 is positioned within residues 143 to 164 of apoA-I, partial LCAT deficiency in the present case is secondary to this substitution and in part is the cause of low plasma HDL levels observed in patients with apoA-I Oita.

Recently, the central amphipathic -helixes have been identified as the functional domains for cholesterol efflux. Monoclonal antibodies with epitopes recognizing amino acid residues 149 to 186 of apoA-I reduce the binding of reconstituted HDL to Hela cells and of cholesterol efflux from adipocytes.⁴¹ On the other hand, the naturally occurring heterozygous apoA-I (Pro165Arg) variant failed to promote cellular cholesterol efflux in murine adipocytes and peritoneal macrophages.⁴² These in vitro studies suggest that central amphipathic -helixes of apoA-I contain several discontinuous, specific regions responsible for the efflux of cellular cholesterol, probably by selectively interacting with the cell surface binding sites. Because apoA-I Oita is located within epitopes of monoclonal antibodies that inhibit cellular cholesterol efflux by apoA-I, apoA-I Oita may be associated with impaired efflux of cellular cholesterol. Hence, low levels of HDL cholesterol in the apoA-I Oita proband may be associated with impaired cholesterol efflux from cells.

Brinton et al⁴³ have recently demonstrated that the level of plasma apoA-I in humans is mainly determined by the FCR of apoA-I. More recently, Miettinen and coworkers¹⁹ showed that the presence of apoA-I (Leu159Arg) Fin was associated with markedly reduced concentrations of plasma apoA-I and HDL cholesterol and increased catabolism of apoA-I in affected heterozygous subjects. They speculated that the moderate hypertriglyceridemia in affected subjects with apoA-I (Leu159Arg) Fin may have contributed to the increased apoA-I FCR and markedly reduced concentration of serum HDL cholesterol. Increased catabolism of apoA-I was also observed in apoA-I (Arg173Cys) Milano, apoA-I (Arg26Gly) Iowa, apoA-I (Lys1070), and in subjects with low HDL cholesterol concentrations.^{43 44 45 46} Turnover studies of isolated apoA-I Milano showed an increased catabolism of the variant apoA-I due to heterodimerization or homodimerization of mutant apoA-I. On the other hand, apoA-I Iowa was shifted to a higher density HDL fraction (HDL₃ and d>1.21 g/mL), whereas the turnover of apoA-I Iowa was faster than that of normal apoA-I in the high- density HDL fraction. In the present case, the distribution of the proband's apoA-I was shifted to a higher density lipoprotein fraction, and gradient gel electrophoresis of HDL particles indicated that HDL particle size was smaller in the apoA-I Oita heterozygote than in normal control subjects. We isolated variant apoA-I Oita from the plasma of the proband and studied its turnover rate in rabbits. The turnover study demonstrated that apoA-I Oita has an accelerated catabolic rate in rabbits compared with normal human apoA-I. The shift of apoA-I to a higher density HDL fraction in the proband with apoA-I Oita may be related to faster catabolism of apoA-I, which may contribute to apoA-I deficiency and low HDL cholesterol levels in our patient.

In the present study, plasma TG of the apoA-I Oita proband was observed mainly in the LDL fraction. A high TG content in the LDL fraction was also observed in Tangier disease and in subjects homozygous for apoA-I (Glu136Lys).^{38 47} Enrichment of TG in the LDL fraction indicates an imbalance of lipid exchange with HDL.

A common genetic polymorphism (-75 G/A) in the apoA-I promoter region was found in the apoA-I Oita proband (II 2) as well as his brother (II 1) and son (III 1). Although previous studies about the impact of the -75 G- to- A mutation in the apoA-I promoter region on HDL cholesterol or apoA-I level are controversial, more recent investigations in genetically homogeneous populations have indicated that the G- to- A mutation does not have a significant direct effect on plasma HDL cholesterol or apoA-I level.^{48 49} Thus, the presence of the -75 G/A polymorphism in the apoA-I Oita family is probably not related to low plasma HDL cholesterol levels in this case.

In conclusion, we analyzed a novel, homozygous, missense point mutation in the apoA-I gene. The Val156Glu substitution in exon 4 of the apoA-I gene in both alleles has a serious impact on HDL metabolism, leading to apoA-I and HDL deficiencies, partial LCAT deficiency, and corneal opacities. The proband also presented with clinical features of arteriosclerosis affecting the coronary, carotid, and vertebral arteries. However, the proband's elder brother, who was homozygous for apoA-I Oita, did not have any symptoms suggestive of CAD. Moreover, the proband had other coronary risk factors apart from his apoA-I deficiency, such as age, smoking, and obesity. Because this family study was limited, the impact of this disorder on coronary atherosclerosis remains unknown at present. Further large- scale family studies are necessary to answer this issue. Nevertheless, the unique case presented in this study provides a good opportunity to understand the structure-function relationship between apoA-I and HDL metabolism.

	Selected Abbreviations and Acronyms

 

CAD = coronary artery disease CER = cholesterol esterification rate FCR = fractional catabolic rate IEF = isoelectric focusing LCAT = lecithin:cholesterol acyltransferase PAGE = polyacrylamide gel electrophoresis PCR = polymerase chain reaction TG = triglyceride

	Acknowledgments

 
This work was partly supported by grants from the Japanese Ministry of Education, Science, Sports, and Culture (No. 08671195 to J.S., No. 08671196 to A.M.) and the Science Research Promotion Fund from the Japan Private School Promotion Foundation. We wish to thank Tomoko Shinkawa for her excellent technical assistance and Haruna Inoue for the preparation of the manuscript.

Received July 22, 1997; accepted November 4, 1997.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211–228.[Abstract]
2. Brouillette CG, Anantharamaiah GM. Structural models of human apolipoprotein A-I. Biochim Biophys Acta. 1995;1256:103–129.[Medline] [Order article via Infotrieve]
3. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation. 1995;91:505–512.[Free Full Text]
4. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Circulation. 1993;87(suppl III):III-28–III-34.
5. Moriyama K, Sasaki J, Takada Y, Matsunaga A, Fukui J, Albers JJ, Arakawa K. A cysteine-containing truncated apoA-I variant associated with HDL deficiency. Arterioscler Thromb Vasc Biol. 1996;16:1416–1423.[Abstract/Free Full Text]
6. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Nofze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary heart disease. N Engl J Med. 1982;306:1513–1519.[Abstract]
7. Karathanasis SK, Ferris E, Haddad IA. DNA inversion within the apolipoproteins A-I/C-III/A-IV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A. 1987;84:7198–7202.[Abstract/Free Full Text]
8. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339–16342.[Abstract/Free Full Text]
9. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamaguchi Y, Tanaka I, Obara T, Hamaguchi H. Apolipoprotein A-I deficiency due to a codon nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci U S A. 1991;88:2793–2797.[Abstract/Free Full Text]
10. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G. A frameshift mutation in the apo A-I gene causes corneal opacities, HDL deficiency and partial LCAT deficiency, a syndrome that is distinct from fish-eye disease. J Clin Invest. 1991;87:375–380.
11. Deeb SS, Cheung MC, Peng R, Wolf AC, Stern R, Albers JJ, Knopp RH. A mutation in the human apolipoprotein A-I gene: dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem. 1991;266:13654–13660.[Abstract/Free Full Text]
12. Lackner KJ, Dieplinger H, Nowicka G, Schmitz G. High density lipoprotein deficiency with xanthomas: a defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest. 1993;92:2262–2273.
13. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q [-2] X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 1994;93:223–229.
14. Römling R, von Eckardstein A, Funke H, Motti C, Fragiacome GC, Nosoda G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb. 1994;14:1915–1922.[Abstract/Free Full Text]
15. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa K. A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol. 1995;15:1866–1874.[Abstract/Free Full Text]
16. von Eckardstein A, Funke H, Walter M, Altland K, Benninghoven A, Assmann G. Structural analysis of human apolipoprotein A-I variants. J Biol Chem. 1990;265:8610–8617.[Abstract/Free Full Text]
17. Aiello DB, Zeller KI, Devlin CM, Friel GA, Miller M. Apolipoprotein A-I Zavalla(Leu159Pro). a novel mutation causing very low HDL cholesterol is associated with premature coronary heart disease. Circulation. 1995;92(suppl I):I-494. Abstract.
18. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling J, Funke H, Wiebusch H, von Eckardstein A, Assmann G. Compound heterozygosity for a structural apolipoprotein A-I variant, apoA-I (L141R) Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation. 1996;94:1622–1628.[Abstract/Free Full Text]
19. Miettinen HE, Gylling H, Miettinen TA, Viikari J, Paulin L, Kontula K. Apolipoprotein A-I Fin: dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene. Arterioscler Thromb Vasc Biol. 1997;17:83–90.[Abstract/Free Full Text]
20. Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A. Heterozygosity for apolipoprotein A-I (R160L) Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I. J Lipid Res. 1997;38:121–131.[Abstract]
21. Bruckert E, von Eckardstein A, Funke H, Beucler I, Wiebusch H, Turpin G, Assmann G. The replacement of arginine by cysteine at residue 151 in apolipoprotein A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis. 1997;128:121–128.[Medline] [Order article via Infotrieve]
22. Utermann G, Haas J, Steinmetz A, Paetzold R, Rall SC Jr, Weisgraber KH Jr, Mahley RW. Apolipoprotein A-I Giessen (Pro143Arg). a mutant that is defective in activating lecithin:cholesterol acyltransferase. Eur J Biochem. 1984;144:325–331.[Medline] [Order article via Infotrieve]
23. Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB, Cerrone A, Menotti A. A-I Milano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083–1097.[Medline] [Order article via Infotrieve]
24. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G. Apolipoprotein A-I variants: naturally occurring substitution of proline residues affect plasma concentrations of apolipoprotein A-I. J Clin Invest. 1989;84:1722–1730.
25. Tilly-Kiesi M, Qiuping Z, Ehnholm S, Kahri J, Lahdenperä S, Ehnholm C, Taskinen M-R. ApoA-I Helsinki (Lys1070) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol. 1995;15:1294–1306.[Abstract/Free Full Text]
26. Takada Y, Sasaki J, Ogata S, Nakanishi T, Ikehara Y, Arakawa K. Isolation and characterization of human apolipoprotein A-I Fukuoka (110 GluLys): a novel apolipoprotein variant. Biochim Biophys Acta. 1990;1043:169–176.[Medline] [Order article via Infotrieve]
27. McFarlane AS. Efficient trace-labeling of proteins with iodine. Nature. 1958;28:53–57.
28. Sasaki J, Cottam GL. Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta. 1982;713:199–207.[Medline] [Order article via Infotrieve]
29. Matthews CME. The theory of tracer experiments with iodine 131-labeled plasma proteins. Phys Med Biol. 1957;2:36–53.[Medline] [Order article via Infotrieve]
30. Moriyama K, Sasaki J, Matsunaga A, Arakawa F, Takada Y, Araki K, Kaneko S Arakawa K. Apolipoprotein E1 Lys-146Glu with type III hyperlipoproteinemia. Biochim Biophys Acta. 1992;1128:58–64.[Medline] [Order article via Infotrieve]
31. Zeng Q, Dammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein C-III marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet. 1995;95:371–375.[Medline] [Order article via Infotrieve]
32. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta. 1981;665:408–419.[Medline] [Order article via Infotrieve]
33. Stokke KT, Norum KR. Determination of lecithin:cholesterol acyltransferase in human blood plasma. Scand J Clin Lab Invest. 1971;27:21–27.[Medline] [Order article via Infotrieve]
34. Moriyama K, Sasaki J, Arakawa F, Takami N, Maeda E, Matsunaga A, Takada Y, Midorikawa K, Yanase T, Yoshino G, Marcovina SM, Albers JJ, Arakawa K. Two novel point mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly344Ser). J Lipid Res. 1995;36:2329–2343.[Abstract]
35. Albers JJ, Adolphson JL, Chen CH. Radioimmunoassay of human lecithin:cholesterol acyltransferase. J Clin Invest. 1981;67:141–146.
36. Shoulders CC, Kornblihtt AR, Munro BS, Baralle FE. Gene structure of human apolipoprotein A-I. Nucleic Acids Res. 1983;11:2827–2837.[Abstract/Free Full Text]
37. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463–5467.[Abstract/Free Full Text]
38. Rall SC Jr, Weisgraber KH, Mahley RW, Ehnholm C, Schamaun O, Olaisen B, Blomhoff JP, Teisberg P. Identification of homozygosity for a human apolipoprotein A-I variant. J Lipid Res. 1986;27:436–441.[Abstract]
39. Minnich A, Collet X, Roghani A, Cladaras C, Hamilton RL, Fielding CJ, Zannis VI. Site-directed mutagenesis and structure function analysis of the human apolipoprotein A-I. J Biol Chem. 1992;267:16553–16560.[Abstract/Free Full Text]
40. Jonas A, von Eckardstein A, Kézdy KE, Steinmetz A, Assmann G. Structural and functional properties of reconstituted high density lipoprotein discs prepared with six apolipoprotein A-I variants. J Lipid Res. 1991;32:97–106.[Abstract]
41. Luchoomun J, Theret N, Clavey V, Duchateau P, Rosseneu M, Brasseur R, Denefle P, Fruchart JC, Castro GR. Structural domain of apolipoprotein A-I involved in its interaction with cells. Biochim Biophys Acta. 1994;1212:319–326.[Medline] [Order article via Infotrieve]
42. von Eckardstein A, Gastro G, Wybranska I, Theret N, Duchateau P, Duverger N, Fruchart JC, Ailhaud G, Assmann G. Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (apoA-I) variants with murine adipocytes and macrophages. J Biol Chem. 1993;268:2616–2622.[Abstract/Free Full Text]
43. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arterioscler Thromb. 1994;14:707–720.[Abstract/Free Full Text]
44. Roma P, Gregg RE, Meng MS, Ronan R, Zech LA, Franceschini G, Sirtori CR, Brewer HB Jr. In vivo metabolism of a mutant form of apolipoprotein A-I, apoA-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest. 1993;91:1445–1452.
45. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, apoA-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res. 1992;33:755–763.[Abstract]
46. Tilly-Kiesi M, Packard CJ, Kahri J, Ehnholm C, Shepherd J, Taskinen M-R. In vivo metabolism of apoA-I and apoA-II in subjects with apoA-I (Lys1070) associated with reduced HDL cholesterol and Lp (AIwAII) deficiency. Atherosclerosis. 1997;128:213–222.[Medline] [Order article via Infotrieve]
47. Heinen RJ, Herbert PN, Frederickson DS, Forte T, Lindgren FT. Properties of the plasma very low and low density lipoproteins in Tangier disease. J Clin Invest. 1978;61:120–132.
48. Minnich A, Delangavant G, Lavigne J, Roederer G, Lussier-Cacan S, Davignon J. GA substitution at position -75 of the apolipoprotein A-I gene promoter. Arterioscler Thromb Vasc Biol. 1995;15:1740–1745.[Abstract/Free Full Text]
49. Akita H, Chiba H, Tsuji M, Hui SP, Takahashi Y, Matsuno K, Kobayashi K. Evaluation of G to A substitution in the apolipoprotein A-I gene promoter as a determinant of high-density lipoprotein cholesterol level in subjects with and without cholesterol ester transfer protein deficiency. Hum Genet. 1995;96:521–526.[Medline] [Order article via Infotrieve]